<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132898">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02013778</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 22213</org_study_id>
    <nct_id>NCT02013778</nct_id>
  </id_info>
  <brief_title>Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC</brief_title>
  <official_title>Phase I-II Clinical Trial of the Safety and Preliminary Efficacy of Hydroxychloroquine Combined With Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Phase I:To determine dose limiting toxicities and maximum tolerated dose (MTD) of
      the oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial
      chemoembolization (TACE) in treating hepatocellular carcinoma (HCC). A conventional 3+3
      design will be utilized.  Primary Phase II: To evaluate the complete response rate in a
      cohort of patients treated at the MTD, A Simon's Optimal Two-stage design will be utilized.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCQ</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient capable of giving informed consent

          -  Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of
             the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with
             classic radiographic findings of arterial phase enhancement with venous phase washout
             and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2
             cm with probable imaging features of HCC and imaging findings of cirrhosis and/or
             portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL.

          -  Patient not candidate for orthotopic liver transplantation at the Hospital of the
             University of Pennsylvania based on review of patient imaging and history at
             multidisciplinary Hepatic Tumor Conference at the Hospital of the University of
             Pennsylvania.

          -  Age 18 years old

          -  Albumin 2.4 g/dL; Total bilirubin  2 mg/dL; INR 1.5

          -  Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L

          -  Child-Turcotte-Pugh Classification A or B

          -  Eastern Clinical Oncology Group performance status 0 or1.

        Exclusion Criteria:

          -  Prior TACE

          -  Active GI hemorrhage within 2 weeks of study enrollment

          -  Ascites refractory to medical therapy

          -  Contraindication to receiving HCQ or TACE

          -  Unilobar HCC

          -  Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)

          -  Women who are pregnant

          -  Participation in another concurrent treatment protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Nadolski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregory Nadolski, MD</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Nadolski, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Nadolski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>outside of transplant criteria</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
